{"id":58525,"date":"2026-03-02T13:26:18","date_gmt":"2026-03-02T05:26:18","guid":{"rendered":"https:\/\/flcube.com\/?p=58525"},"modified":"2026-03-02T13:26:19","modified_gmt":"2026-03-02T05:26:19","slug":"ql-biopharma-raises-500m-rmb-series-c-orbimed-leads-round-for-monthly-glp-1-zovigrutide","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58525","title":{"rendered":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide"},"content":{"rendered":"\n<p><strong>Beijing QL Biopharmaceutical Co., Ltd.<\/strong> announced the completion of a <strong>Series C financing round<\/strong> raising <strong>over 500\u202fmillion RMB<\/strong> (~\u202fUSD\u202f70\u202fmillion). The round was <strong>led by OrbiMed<\/strong>, with participation from <strong>Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital<\/strong>, and prominent industrial funds. Existing shareholders <strong>TF Capital, BlueRun Ventures, and Taiyu Investment<\/strong> increased their stakes. <strong>Haoyue Capital<\/strong> served as exclusive financial advisor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Beijing QL Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td><strong>&gt;\u202f500\u202fmillion RMB<\/strong> (~\u202fUSD\u202f70\u202fmillion)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>OrbiMed<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, industrial funds<\/td><\/tr><tr><td><strong>Existing Shareholders (Increased Stakes)<\/strong><\/td><td>TF Capital, BlueRun Ventures, Taiyu Investment<\/td><\/tr><tr><td><strong>Financial Advisor<\/strong><\/td><td>Haoyue Capital<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-focus-chronic-metabolic-diseases\">Therapeutic Focus \u2013 Chronic Metabolic Diseases<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Technology Platform<\/th><th>Application<\/th><\/tr><\/thead><tbody><tr><td><strong>Ultra\u2011Long\u2011Acting<\/strong><\/td><td>Extended dosing intervals improving patient compliance<\/td><\/tr><tr><td><strong>Oral Peptide<\/strong><\/td><td>Non\u2011invasive delivery of peptide therapeutics<\/td><\/tr><tr><td><strong>Multi\u2011Target Therapies<\/strong><\/td><td>Combination mechanisms for comprehensive metabolic control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-zovigrutide-zt002\">Lead Asset \u2013 Zovigrutide (ZT002)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Generic Name<\/strong><\/td><td>Zovigrutide (ZT002)<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td><strong>GLP\u20111 receptor agonist (GLP\u20111RA)<\/strong><\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Monthly administration<\/strong> (vs. weekly or daily competitors)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Weight management<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Phase III (HORIZON\u20111 study) ongoing in China<\/td><\/tr><tr><td><strong>Market Potential<\/strong><\/td><td><strong>World&#8217;s first once\u2011monthly GLP\u20111 peptide<\/strong> if approved<\/td><\/tr><tr><td><strong>Competitive Context<\/strong><\/td><td>Challenges semaglutide (weekly), tirzepatide (weekly), and oral alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monthly Dosing Disruption:<\/strong> <strong>Once\u2011monthly GLP\u20111 administration<\/strong> could fundamentally transform patient adherence and market dynamics, reducing injection burden and healthcare system costs associated with frequent clinic visits.<\/li>\n\n\n\n<li><strong>OrbiMed Validation:<\/strong> <strong>OrbiMed&#8217;s lead participation<\/strong>\u2014a top\u2011tier global healthcare investor\u2014signals strong confidence in QL Biopharma&#8217;s <strong>ultra\u2011long\u2011acting platform<\/strong> and Zovigrutide&#8217;s blockbuster potential.<\/li>\n\n\n\n<li><strong>China\u2011First Strategy:<\/strong> <strong>Phase III in China<\/strong> positions QL Biopharma for <strong>domestic market approval<\/strong> ahead of global competitors, with potential for <strong>out\u2011licensing<\/strong> ex\u2011China rights to multinational partners.<\/li>\n\n\n\n<li><strong>Metabolic Portfolio Depth:<\/strong> The <strong>ultra\u2011long\u2011acting + oral peptide + multi\u2011target<\/strong> technology stack supports <strong>pipeline expansion<\/strong> beyond GLP\u20111 into GIP, glucagon, and combination therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>GLP\u20111 Market Size<\/strong><\/td><td>&gt;\u202f$100\u202fbillion projected by 2030; dosing convenience drives competitive differentiation<\/td><\/tr><tr><td><strong>Monthly Administration Advantage<\/strong><\/td><td>4x dosing frequency reduction vs. weekly injections; potential for 30\u201140% adherence improvement<\/td><\/tr><tr><td><strong>China Obesity Burden<\/strong><\/td><td>World&#8217;s largest overweight\/obese population; domestic innovation increasingly prioritized<\/td><\/tr><tr><td><strong>Investor Appetite<\/strong><\/td><td>Metabolic disease biotechs commanding premium valuations; OrbiMed participation validates QL&#8217;s platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III enrollment, regulatory pathways, and commercial potential for Zovigrutide. Actual results may differ due to risks including competitive weekly GLP\u20111 launches, manufacturing scale\u2011up for monthly dosing formulations, and long\u2011term safety monitoring requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1877],"class_list":["post-58525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ql-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58525\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide\" \/>\n<meta property=\"og:description\" content=\"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58525\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T05:26:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T05:26:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide\",\"datePublished\":\"2026-03-02T05:26:18+00:00\",\"dateModified\":\"2026-03-02T05:26:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0203.webp\",\"keywords\":[\"QL Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58525#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58525\",\"name\":\"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0203.webp\",\"datePublished\":\"2026-03-02T05:26:18+00:00\",\"dateModified\":\"2026-03-02T05:26:19+00:00\",\"description\":\"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58525\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0203.webp\",\"width\":1080,\"height\":608,\"caption\":\"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58525#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58525","og_locale":"en_US","og_type":"article","og_title":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide","og_description":"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.","og_url":"https:\/\/flcube.com\/?p=58525","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T05:26:18+00:00","article_modified_time":"2026-03-02T05:26:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58525#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58525"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide","datePublished":"2026-03-02T05:26:18+00:00","dateModified":"2026-03-02T05:26:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58525"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58525#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","keywords":["QL Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58525#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58525","url":"https:\/\/flcube.com\/?p=58525","name":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58525#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58525#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","datePublished":"2026-03-02T05:26:18+00:00","dateModified":"2026-03-02T05:26:19+00:00","description":"Beijing QL Biopharmaceutical Co., Ltd. announced the completion of a Series C financing round raising over 500\u202fmillion RMB (~\u202fUSD\u202f70\u202fmillion). The round was led by OrbiMed, with participation from Qiming Venture Partners, 5Y Capital, Aprobiotech, Huagai Capital, and prominent industrial funds. Existing shareholders TF Capital, BlueRun Ventures, and Taiyu Investment increased their stakes. Haoyue Capital served as exclusive financial advisor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58525#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58525"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58525#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","width":1080,"height":608,"caption":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58525#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"QL Biopharma Raises 500M+ RMB Series C \u2013 OrbiMed Leads Round for Monthly GLP\u20111 Zovigrutide"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58525"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58525\/revisions"}],"predecessor-version":[{"id":58529,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58525\/revisions\/58529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58528"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}